PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.09%
R&D reduction while AXSM shows 10.62% growth. Joel Greenblatt would examine competitive risk.
3.56%
G&A change of 3.56% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-26.91%
Operating expenses reduction while AXSM shows 6.62% growth. Joel Greenblatt would examine advantage.
-26.91%
Total costs reduction while AXSM shows 8.31% growth. Joel Greenblatt would examine advantage.
10.26%
Interest expense growth less than half of AXSM's 24.56%. David Dodd would verify sustainability.
-96.48%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-115.63%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
27.06%
Similar operating income growth to AXSM's 35.57%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
-198.08%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-304.05%
Pre-tax income decline while AXSM shows 17.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
113.79%
Tax expense change of 113.79% while AXSM maintains burden. Bruce Berkowitz would investigate strategy.
-304.05%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-302.06%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-288.66%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
0.11%
Share count reduction exceeding 1.5x AXSM's 1.17%. David Dodd would verify capital allocation.
3.68%
Diluted share reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.